Jacobs Levy Equity Management Inc. Takes $28.31 Million Position in Moderna, Inc. $MRNA

Key Points

• Jacobs Levy Equity Management Inc. has invested $28.31 million in Moderna, acquiring 998,503 shares, which represents 0.26% ownership of the company.
• Several institutional investors are actively increasing their holdings in Moderna, with Deutsche Bank raising its stake by 54.7% in the last quarter, now owning 1,894,075 shares.
• Moderna reported a quarterly revenue of $142 million, surpassing analyst estimates, but still showed a significant year-over-year decline of 41.1%.

Jacobs Levy Equity Management Inc. purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 998,503 shares of the company's stock, valued at approximately $28,308,000. Jacobs Levy Equity Management Inc. owned about 0.26% of Moderna as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Ameriprise Financial Inc. raised its stake in shares of Moderna by 10.8% in the fourth quarter. Ameriprise Financial Inc. now owns 235,280 shares of the company's stock worth $9,784,000 after acquiring an additional 23,007 shares during the last quarter. Cetera Investment Advisers raised its stake in shares of Moderna by 8.3% in the fourth quarter. Cetera Investment Advisers now owns 40,783 shares of the company's stock worth $1,696,000 after acquiring an additional 3,121 shares during the last quarter. Crestline Management LP bought a new position in shares of Moderna in the fourth quarter worth about $796,000. Deutsche Bank AG raised its stake in shares of Moderna by 54.7% in the fourth quarter. Deutsche Bank AG now owns 1,894,075 shares of the company's stock worth $78,756,000 after acquiring an additional 669,614 shares during the last quarter. Finally, FORA Capital LLC bought a new position in shares of Moderna in the fourth quarter worth about $3,066,000. 75.33% of the stock is owned by institutional investors.

Moderna Stock Up 2.5%

NASDAQ MRNA traded up $0.62 during trading on Thursday, reaching $24.93. 4,946,459 shares of the stock traded hands, compared to its average volume of 10,704,837. The firm has a market cap of $9.70 billion, a price-to-earnings ratio of -3.32 and a beta of 1.93. The stock's 50-day moving average price is $28.58 and its 200 day moving average price is $28.34. Moderna, Inc. has a fifty-two week low of $23.15 and a fifty-two week high of $75.37.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share for the quarter, beating the consensus estimate of ($2.99) by $0.86. The company had revenue of $142.00 million during the quarter, compared to analysts' expectations of $116.26 million. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The business's quarterly revenue was down 41.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($3.33) earnings per share. Moderna has set its FY 2025 guidance at EPS. Analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on MRNA. Citigroup assumed coverage on shares of Moderna in a research note on Friday, August 1st. They issued a "neutral" rating and a $40.00 target price for the company. Cowen assumed coverage on shares of Moderna in a research note on Sunday, July 13th. They set a "hold" rating for the company. Wells Fargo & Company reissued an "equal weight" rating on shares of Moderna in a research note on Sunday, July 13th. Bank of America dropped their price target on shares of Moderna from $26.00 to $25.00 and set an "underperform" rating for the company in a research note on Tuesday, July 22nd. Finally, JPMorgan Chase & Co. set a $26.00 price target on shares of Moderna in a research note on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, sixteen have assigned a Hold rating and four have given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $42.88.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.